SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020-2022

Emerg Infect Dis. 2023 Nov;29(11):2257-2265. doi: 10.3201/eid2911.230577.

Abstract

Understanding if persons with HIV (PWH) have a higher risk for SARS-CoV-2 reinfection may help tailor future COVID-19 public health guidance. To determine whether HIV infection was associated with increased risk for SARS-CoV-2 reinfection, we followed adult residents of Chicago, Illinois, USA, with SARS-CoV-2 longitudinally from their first reported infection through May 31, 2022. We matched SARS-CoV-2 laboratory data and COVID-19 vaccine administration data to Chicago's Enhanced HIV/AIDS Reporting System. Among 453,587 Chicago residents with SARS-CoV-2, a total of 5% experienced a SARS-CoV-2 reinfection, including 192/2,886 (7%) PWH and 23,642/450,701 (5%) persons without HIV. We observed higher SARS-CoV-2 reinfection incidence rates among PWH (66 [95% CI 57-77] cases/1,000 person-years) than PWOH (50 [95% CI 49-51] cases/1,000 person-years). PWH had a higher adjusted rate of SARS-CoV-2 reinfection (1.46, 95% CI 1.27-1.68) than those without HIV. PWH should follow the recommended COVID-19 vaccine schedule, including booster doses.

Keywords: COVID-19; Chicago; HIV/AIDS; Illinois; PWH; PWOH; SARS-CoV-2; United States; public health surveillance; reinfection; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.

MeSH terms

  • Adult
  • COVID-19 Vaccines
  • COVID-19* / epidemiology
  • COVID-19* / prevention & control
  • Chicago / epidemiology
  • HIV Infections* / complications
  • HIV Infections* / epidemiology
  • Humans
  • Illinois / epidemiology
  • Reinfection / epidemiology
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines